United Orthopedic Corporation held an investor conference on Nov 27. Chairman Lin Yen-sheng stated that despite a high baseline from doubled revenue over the past three years, the company expects approximately 20% revenue growth in 2026. To support this, United will initiate the construction of Kaohsiung Plant II, with production expected to commence by 2028. Growth drivers will primarily stem from Europe, the Americas, Japan, and new product launches.

Market and Strategy Highlights:

• Regional Mix: As of Q3 2024, revenue distribution stands at Asia-Pacific (44%), EMEA (35%), and the Americas (21%).
• Direct Sales Model: 80% of revenue comes from direct-sales markets (subsidiaries). While this requires higher initial investment and a 5–6 year break-even period, it is critical for building surgeon trust and deep market penetration.
• Pipeline: Key 2026 certifications include the U-Motion Acetabular System (modular design for clinical flexibility) and the 3D-printed Reconstructive Conical System (mimicking cancellous bone structure for enhanced osseointegration).
• Surgical Robotics & Navigation: United has been developing a proprietary surgical navigation system for nearly a year, with the first product launch expected next year. It will eventually integrate with robotic arms to improve surgical precision.
• China Market Shift: Due to the Volume-Based Procurement (VBP) policy in China, prices have plummeted to NT$20k–30k per set, compared to €2,000–3,000 in Europe and $3,000–4,000 in the U.S. Consequently, United has de-emphasized China in its global strategy.

Resource: 聯合骨材董座林延生：明年營業額估將增20% 啟動高雄二廠計畫